Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-602 Alone and with Cemiplimab in Advanced Cancers
NCT05259696Phase 2Completed
- Sponsor
- Palleon Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efgitasialase alfa in melanoma, ovarian cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), sponsored by Palleon Pharmaceuticals. Started Feb 2022; status: completed.
02
Drugs
efgitasialase alfa
03
Conditions
melanomaovarian cancernon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05259696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259696.